Stockscreener 앱 받기
118.84
0.56%
-0.67
전일 마감가:
$119.51
열려 있는:
$119.13
하루 거래량:
1.54M
Relative Volume:
0.96
시가총액:
$17.05B
수익:
$9.61B
순이익/손실:
$1.62B
주가수익비율:
10.74
EPS:
11.07
순현금흐름:
$1.77B
1주 성능:
+0.19%
1개월 성능:
-14.60%
6개월 성능:
-34.59%
1년 성능:
-41.30%
1일 변동 폭
$117.14
$119.62
1주일 범위
$115.44
$121.75
52주 변동 폭
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
명칭
Biogen Inc
전화
(781) 464-2000
주소
225 BINNEY STREET, CAMBRIDGE, MA
BIIB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
118.84 | 17.05B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
884.54 | 794.47B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
154.58 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.06 | 301.01B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
62.08 | 258.93B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
112.14 | 218.33B | 51.72B | 11.94B | 13.81B | 5.88 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-04 | 다운그레이드 | Argus | Buy → Hold |
| 2025-02-11 | 개시 | Bernstein | Mkt Perform |
| 2025-01-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-11-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-02-14 | 재확인 | Needham | Buy |
| 2024-02-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-12-20 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-12-07 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-24 | 재확인 | UBS | Buy |
| 2023-05-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-04-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-10-13 | 업그레이드 | Stifel | Hold → Buy |
| 2022-10-07 | 업그레이드 | Argus | Hold → Buy |
| 2022-09-28 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-28 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 재확인 | Barclays | Equal Weight |
| 2022-02-04 | 재확인 | BofA Securities | Neutral |
| 2022-02-04 | 재확인 | Cowen | Outperform |
| 2022-02-04 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-04 | 재확인 | Needham | Buy |
| 2022-02-04 | 재확인 | Oppenheimer | Outperform |
| 2022-02-04 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 재확인 | Robert W. Baird | Neutral |
| 2022-02-04 | 재확인 | Wedbush | Neutral |
| 2022-02-04 | 재확인 | Wells Fargo | Equal Weight |
| 2022-02-04 | 재확인 | Wolfe Research | Peer Perform |
| 2022-01-13 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-01-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-06-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 재확인 | Truist | Buy |
| 2021-06-11 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-08 | 업그레이드 | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 재확인 | Barclays | Equal Weight |
| 2021-06-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-08 | 재확인 | Jefferies | Buy |
| 2021-06-08 | 재확인 | Morgan Stanley | Overweight |
| 2021-06-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 재확인 | Stifel | Buy |
| 2021-06-08 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-07 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-06-07 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-01-29 | 업그레이드 | Stifel | Hold → Buy |
| 2020-11-10 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-11-09 | 다운그레이드 | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-11-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-11-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-04 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-11-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-11-04 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-07-27 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-04-23 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-27 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
모두보기
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen (BIIB) to Release Quarterly Earnings on Thursday - MarketBeat
CANADA LIFE ASSURANCE Co Reduces Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ossiam Buys 2,653 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Envestnet Asset Management Inc. Reduces Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cognitive Impairment Market Is Booming Worldwide 2025-2032 | Eisai Co., Biogen Inc., Novartis AG - openPR.com
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (NASDAQ:BIIB) - Seeking Alpha
T. Rowe Price Investment Management Inc. Has $474.02 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Pinebridge Investments L.P. Has $38.20 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market: Growth, Trends, - openPR.com
RBC Cuts Price Target on Biogen to $217 From $225, Keeps Outperform Rating - marketscreener.com
Commerce Bank Sells 2,830 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Royal Bank of Canada Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Spinal Muscular Atrophy Market Deep Research with Forecast, - openPR.com
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline - Yahoo Finance
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore - Yahoo Finance
Can Biogen Keep the Beat Streak Alive This Earnings Season? - TradingView
J. Safra Sarasin Holding AG Cuts Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Natixis Has $4.34 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
First Trust Advisors LP Increases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Friedreich’s ataxia treatment authorised in UK - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat
Neurodegenerative Disease Market Key Players Analysis - openPR.com
Biogen Inc. (NASDAQ:BIIB) Stock Position Reduced by United Capital Financial Advisors LLC - MarketBeat
Biosimilars Market Expansion in 2025: The Next Big Thing - openPR.com
Biogen Obtains UK Marketing Clearance for Friedreich's Ataxia Treatment - marketscreener.com
Crohn's Disease Market Growth, Trends & Forecast 2025 | Top key - openPR.com
Wedbush Issues Positive Outlook for Biogen Earnings - MarketBeat
14 Analysts Have This To Say About Biogen - Benzinga
Erythromelalgia Treatment Market Overall Study Report - openPR.com
Inflammatory Bowel Disease Market Growth, Trends & Forecast 2025 | Top key playersPfizer Inc, Biogen, Novartis AG. - openPR.com
RBC Lifts Price Target on Biogen to $225 From $221, Keeps Outperform Rating - marketscreener.com
Townsquare Capital LLC Sells 9,997 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedbush Predicts Biogen's Q1 Earnings (NASDAQ:BIIB) - MarketBeat
Earnings Preview: What To Expect From Biogen's Report - MSN
Bleeding Disorders Treatment Market Set to Witness Significant - openPR.com
Biogen (NASDAQ:BIIB) shareholders have endured a 61% loss from investing in the stock five years ago - simplywall.st
Canada Pension Plan Investment Board Boosts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Raymond James Financial Inc. Purchases Shares of 141,968 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
PEGylated Proteins Market Positioned for Accelerated Growth - openPR.com
Canada Post Corp Registered Pension Plan Acquires Shares of 9,718 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sterling Capital Management LLC Has $1.32 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Leerink Partnrs Has Bearish Estimate for Biogen Q2 Earnings - MarketBeat
Biogen/ Eisai win EU approval for Alzheimer’s therapy - MSN
Jump Financial LLC Grows Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc (BIIB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.28%
0.61%
자본화:
|
볼륨(24시간):